Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy

Madrigal Pharmaceuticals Inc. shares soared as much as 145% in extremely heavy Thursday trade after the company released positive results for a phase 2 clinical trial for a type of liver disease called non-alcoholic steatohepatitis, or NASH.